BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:08 PM
 | 
May 19, 2019
 |  BioCentury  |  Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri.

On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million) seed round in Rinri Therapeutics Ltd. with UCB Ventures and participation by BioCity.

Boehringer's Detlev Mennerich told BioCentury that the fund first came across the technology, developed by Sheffield University professor Marcelo Rivolta, as it was conducting due diligence for...

Read the full 352 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >